Red5 Pharmaceuticals LLC, a 杏吧视频-based biopharmaceutical startup, was among 35 companies chosen from 200 applicants nationally to be featured as part of the first University Startups Demo Day in Washington, D.C., in September.
The event was produced by the National Council of Entrepreneurial Tech Transfer (NCET2), an association of university startup officers.
Universities create more than 800 startups nationally each year, according to NCET2. Two-hundred companies submitted applications and were screened to find the 鈥淏est University Startups 2016鈥 to be showcased at the Demo Day.
鈥淚t is both exciting and quite an honor to have one of our startup companies featured in this inaugural event,鈥 said Michael Haag, 杏吧视频鈥檚 executive director for .
develops a diagnostic procedure that can be used during chemotherapy, which encompasses a patented DNA modification technology. The use of Red5鈥檚 patented procedure allows for a personalized medicine approach to chemotherapy鈥攖he customization of patient health care by tailoring specific treatment decisions and practices to an individual.
Founded in late 2013, Red5 has licensed patented technology discovered by the company鈥檚 co-founder, Chief Scientific Officer Anthony Berdis, at 杏吧视频 School of Medicine, where he was an assistant professor of pharmacology. Berdis devoted his research to exploring the mechanism and dynamics of precise and pro-mutagenic DNA synthesis.
The company鈥檚 lead product is its trademarked KRun kit. The product uses patented chemicals to assess patient samples (blood, serum or tumor biopsy) and determine whether a particular chemotherapy program will be effective at treating leukemias, lymphomas and solid tumors. The kit will provide oncologists with essential information to make rapid clinical decisions.
鈥淧resenting at NCET2 was a great opportunity for Red5 to continue to attract funding from venture capitalists and angel investors,鈥 Berdis said. 鈥淭hese investments will help further develop and commercialize our novel diagnostic kit.鈥
In 2014, Red5 Pharmaceuticals was awarded a $25,000 grant from Great Lakes Innovation and Development Enterprise to develop the enzymatic assays for the KRun kit. In 2015, the Cleveland-based company was awarded a $60,000 Technology Validation and Start-up Fund grant from Ohio Third Frontier to further develop a sensor kit to predict whether or not a patient鈥檚 leukemia or brain cancer will respond to a specific chemotherapy regimen prior to starting treatment.
"To lead the world in the 21st century, our nation must have a sustained commitment to education, scientific research and startups," said NCET2 Executive Director Tony Stanco, 鈥渁nd American universities are uniquely positioned to deliver on all three to ensure the U.S. continues to lead socially and economically in this century, as it did in the last.鈥
杏吧视频 provides a robust environment for students, faculty researchers and alumni to innovate and develop their ideas into university-based startups鈥攊ncluding the multi-story Larry Sears and Sally Zlotnick Sears think[box] 鈥渕akerspace,鈥 CWRU LaunchNet and the university鈥檚 Technology Transfer Office, among many other facilities and programs.
This article was originally published Sept. 27.
CWRU-based biopharmaceutical startup showcased at national Demo Day
Red5 Pharmaceuticals LLC, a 杏吧视频-based biopharmaceutical startup, was among 35 companies chosen from 200 applicants nationally to be featured as part of the first University Startups Demo Day in Washington, D.C., in September.
The event was produced by the National Council of Entrepreneurial Tech Transfer (NCET2), an association of university startup officers.
Universities create more than 800 startups nationally each year, according to NCET2. Two-hundred companies submitted applications and were screened to find the 鈥淏est University Startups 2016鈥 to be showcased at the Demo Day.
鈥淚t is both exciting and quite an honor to have one of our startup companies featured in this inaugural event,鈥 said Michael Haag, 杏吧视频鈥檚 executive director for .
develops a diagnostic procedure that can be used during chemotherapy, which encompasses a patented DNA modification technology. The use of Red5鈥檚 patented procedure allows for a personalized medicine approach to chemotherapy鈥攖he customization of patient health care by tailoring specific treatment decisions and practices to an individual.
Founded in late 2013, Red5 has licensed patented technology discovered by the company鈥檚 co-founder, Chief Scientific Officer Anthony Berdis, at 杏吧视频 School of Medicine, where he was an assistant professor of pharmacology. Berdis devoted his research to exploring the mechanism and dynamics of precise and pro-mutagenic DNA synthesis.
The company鈥檚 lead product is its trademarked KRun kit. The product uses patented chemicals to assess patient samples (blood, serum or tumor biopsy) and determine whether a particular chemotherapy program will be effective at treating leukemias, lymphomas and solid tumors. The kit will provide oncologists with essential information to make rapid clinical decisions.
鈥淧resenting at NCET2 was a great opportunity for Red5 to continue to attract funding from venture capitalists and angel investors,鈥 Berdis said. 鈥淭hese investments will help further develop and commercialize our novel diagnostic kit.鈥
In 2014, Red5 Pharmaceuticals was awarded a $25,000 grant from Great Lakes Innovation and Development Enterprise to develop the enzymatic assays for the KRun kit. In 2015, the Cleveland-based company was awarded a $60,000 Technology Validation and Start-up Fund grant from Ohio Third Frontier to further develop a sensor kit to predict whether or not a patient鈥檚 leukemia or brain cancer will respond to a specific chemotherapy regimen prior to starting treatment.
"To lead the world in the 21st century, our nation must have a sustained commitment to education, scientific research and startups," said NCET2 Executive Director Tony Stanco, 鈥渁nd American universities are uniquely positioned to deliver on all three to ensure the U.S. continues to lead socially and economically in this century, as it did in the last.鈥
杏吧视频 provides a robust environment for students, faculty researchers and alumni to innovate and develop their ideas into university-based startups鈥攊ncluding the multi-story Larry Sears and Sally Zlotnick Sears think[box] 鈥渕akerspace,鈥 CWRU LaunchNet and the university鈥檚 Technology Transfer Office, among many other facilities and programs.
This article was originally published Sept. 27.
